The significant EPS miss and widening operating losses are concerning, but the $72.4M cash runway to mid-2029 and upcoming SCY-770 Phase 2 catalyst in Q4 2026 provide a long development horizon. Monitor for topline Phase 1 IV data for SCY-247 in Q3 2026 and any GSK Brexafemme relaunch milestones that could trigger revenue.
SCYX drugs
SCYX drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 12 $6.24entry
- T+1 · 6mo ago −2.44%α −3.00% · $6.09
- T+5 · 6mo ago −15.77%α −15.17% · $5.26
- T+20 · 5mo ago −33.49%α −31.77% · $4.15
- T+60 · 3mo ago −16.67%α −21.05% · $5.20
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
SCYNEXIS reported Q1 2026 results with a GAAP net loss of $0.42 per share, significantly wider than the consensus estimate of -$0.12, driven by a $8.0M IPR&D charge for the SCY-770 acquisition and a $5.2M warrant liability fair value adjustment. The company completed a $37.2M private placement and ended the quarter with $72.4M in cash, extending its runway to mid-2029, but the core operating loss more than doubled year-over-year with no revenue.
Key Financial Metrics
Key Facts
- GAAP net loss per share of -$0.42 vs consensus of -$0.12 (250% miss)
- Net loss of $21.3M vs $5.4M in Q1 2025, driven by $8.0M IPR&D charge for SCY-770 acquisition and $5.2M warrant liability adjustment
- Revenue was $0 vs $0.3M in Q1 2025 (no license revenue recognized)
- Completed $37.2M private placement on April 1, 2026, with potential for additional $52.2M from warrant exercises
- Cash, cash equivalents and investments of $72.4M at March 31, 2026, extending cash runway to mid-2029
- GSK committed to Brexafemme relaunch with potential up to $146M in annual net sales milestones
- Phase 2 proof-of-concept study for SCY-770 in ADPKD expected to begin Q4 2026 with early efficacy readout in H2 2027
Financial Impact
Net loss widened to $21.3M from $5.4M YoY; EPS miss of -$0.42 vs -$0.12 consensus; cash position $72.4M post-offering
Risk Factors
- No near-term revenue visibility; operating losses expected to continue
- SCY-770 Phase 2 proof-of-concept study carries clinical and regulatory risk
- Warrant liability fair value adjustment creates earnings volatility tied to stock price
- Dilution risk from potential full exercise of $52.2M in warrants
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292371 |
Track record
14 reports on SCYX
4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +12.34% at T+5 after the Mar 4, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.91 Now $2.91 +0.00% settles Nov 24
- Nov 5, 202611d ago S-3 Neutral 3/10 Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
- Oct 22, 202625d ago Press Release Bullish 7/10 Entry $3.81 to $3.86 Now $2.91 −23.62% ▲ +1.31% +0.61% vs SPY
- Oct 6, 20265w ago Press Release Neutral 4/10 Entry $4.84 to $3.99 Now $2.91 −39.88% ▼ −17.56% −17.42% vs SPY
- Sep 28, 20267w ago Press Release Bullish 6/10 Entry $4.62 to $5.03 Now $2.91 −37.01% ▲ +8.87% +7.67% vs SPY
- Sep 22, 20267w ago 8-K Neutral 2/10 Entry $4.86 to $4.66 Now $2.91 −40.12% ▼ −4.12% −2.93% vs SPY
- Sep 10, 20269w ago 8-K Neutral 2/10 Entry $4.70 to $4.45 Now $2.91 −38.09% ▼ −5.32% −4.82% vs SPY
- Jun 26, 202620w ago 8-K Neutral 3/10 Entry $3.87 to $4.73 Now $2.91 −24.81% ▲ +22.22% +20.83% vs SPY
- May 22, 202625w ago 8-K Neutral 4/10 Entry $5.45 to $5.33 Now $2.91 −46.59% ▼ −2.17% −3.25% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers